DECN to Discuss Three Major Events After Memorial Day Holiday Company Plans to Communicate 3rd Offer for the Monitizing Its New "TBG" Products, Developments in Big Box Efforts And the J&J Litigation
LOS ANGELES, CA - May 23, 2019 - Decision Diagnostics Corp. (OTC: DECN) – Keith Berman CEO of the FDA registered 17 year old, diabetes-focused bio-technology R&D firm, manufacturer, etc is announcing that beginning next week we will discuss the following issues in detail, Read More. See Complete Information: http://www.thestreetnow.com/spotlight/dailynews/
Disclaimer: I post on stocks that I own or am thinking about owning, I am not paid to post about them. If that changes you can find the disclosure in my IRP page. Do your DD, buy and sell based on that DD.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.